Salvage surgery for advanced non-small cell lung cancer after response to gefitinib.
Hishida
Tomoyuki
T
Division of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. thishida@nifty.com
Nagai
Kanji
K
Mitsudomi
Tetsuya
T
Yokoi
Kohei
K
Kondo
Haruhiko
H
Horinouchi
Hirohisa
H
Akiyama
Hirohiko
H
Nagayasu
Takeshi
T
Tsuboi
Masahiro
M
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000556:secondary / Q000601:surgery*; D018572:Disease-Free Survival; D066246:ErbB Receptors / Q000235:genetics; D005260:Female; D000077156:Gefitinib; D006801:Humans; D007564:Japan; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009364:Neoplasm Recurrence, Local / Q000601:surgery; D009367:Neoplasm Staging; D018365:Neoplasm, Residual / Q000601:surgery; D011013:Pneumonectomy / Q000009:adverse effects / Q000401:mortality; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D016879:Salvage Therapy; D013997:Time Factors; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; C512478:EGFR protein, human; D066246:ErbB Receptors; D000077156:Gefitinib